{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:18:06Z","timestamp":1793812686715,"version":"4.6.1"},"reference-count":79,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>T cell exhaustion compromises antitumor immunity, and a sustained elevation of co-inhibitory receptors is a hallmark of T cell exhaustion in solid tumors. Similarly, upregulation of co-inhibitory receptors has been reported in T cells in hematological cancers such as chronic lymphocytic leukemia (CLL). However, the role of CD160, a glycosylphosphatidylinositol-anchored protein, as one of these co-inhibitory receptors has been contradictory in T cell function. Therefore, we decided to elucidate how CD160 expression and\/or co-expression with other co-inhibitory receptors influence T cell effector functions in patients with CLL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied 56 patients with CLL and 25 age-matched and sex-matched healthy controls in this study. The expression of different co-inhibitory receptors was analyzed in T cells obtained from the peripheral blood or the bone marrow. Also, we quantified the properties of extracellular vesicles (EVs) in the plasma of patients with CLL versus healthy controls. Finally, we measured 29 different cytokines, chemokines or other biomarkers in the plasma specimens of patients with CLL and healthy controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that CD160 was the most upregulated co-inhibitory receptor in patients with CLL. Its expression was associated with an exhausted T cell phenotype. CD160<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup>T cells were highly antigen-experienced\/effector T cells, while CD160<jats:sup>+<\/jats:sup>CD4<jats:sup>+<\/jats:sup>T cells were more heterogeneous. In particular, we identified EVs as a source of CD160 in the plasma of patients with CLL that can be taken up by T cells. Moreover, we observed a dominantly proinflammatory cytokine profile in the plasma of patients with CLL. In particular, interleukin-16 (IL-16) was highly elevated and correlated with the advanced clinical stage (Rai). Furthermore, we observed that the incubation of T cells with IL-16 results in the upregulation of CD160.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study provides a novel insight into the influence of CD160 expression\/co-expression with other co-inhibitory receptors in T cell effector functions in patients with CLL. Besides, IL-16-mediated upregulation of CD160 expression in T cells highlights the importance of IL-16\/CD160 as potential immunotherapy targets in patients with CLL. Therefore, our findings propose a significant role for CD160 in T cell exhaustion in patients with CLL.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jitc-2020-002189","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T15:21:51Z","timestamp":1619796111000},"page":"e002189","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":50,"title":["Expanded antigen-experienced CD160<sup>+<\/sup>CD8<sup>+<\/sup>effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia"],"prefix":"10.1136","volume":"9","author":[{"given":"Najmeh","family":"Bozorgmehr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isobel","family":"Okoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaide","family":"Oyegbami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanette","family":"Cox-Kennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loree M","family":"Larratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hnatiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Fagarasanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Brandwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthea C","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7215-2009","authenticated-orcid":false,"given":"Shokrollah","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"2021043008200710000_9.4.e002189.1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120833"},{"key":"2021043008200710000_9.4.e002189.2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","article-title":"Chronic lymphocytic leukaemia","volume":"104","author":"Scarf\u00f2","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021043008200710000_9.4.e002189.3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051825","article-title":"Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions","volume":"21","author":"Arruga","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2021043008200710000_9.4.e002189.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-299321"},{"key":"2021043008200710000_9.4.e002189.5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.01639.x"},{"key":"2021043008200710000_9.4.e002189.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-411678"},{"key":"2021043008200710000_9.4.e002189.7","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"2021043008200710000_9.4.e002189.8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01215"},{"key":"2021043008200710000_9.4.e002189.9","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035"},{"key":"2021043008200710000_9.4.e002189.10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-041015-055318"},{"key":"2021043008200710000_9.4.e002189.11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151100"},{"key":"2021043008200710000_9.4.e002189.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457531"},{"key":"2021043008200710000_9.4.e002189.13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41375-018-0250-6","article-title":"Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"key":"2021043008200710000_9.4.e002189.14","doi-asserted-by":"publisher","DOI":"10.111\/bjh.13467"},{"key":"2021043008200710000_9.4.e002189.15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.3.1121"},{"key":"2021043008200710000_9.4.e002189.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2006.04.006"},{"key":"2021043008200710000_9.4.e002189.17","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/jid.2010.412","article-title":"Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160","volume":"131","author":"Ortonne","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2021043008200710000_9.4.e002189.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-334326"},{"key":"2021043008200710000_9.4.e002189.19","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0217-y"},{"key":"2021043008200710000_9.4.e002189.20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1293"},{"key":"2021043008200710000_9.4.e002189.21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.7.4426"},{"key":"2021043008200710000_9.4.e002189.22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131601"},{"key":"2021043008200710000_9.4.e002189.23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41423-019-0241-1","article-title":"HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and light","volume":"16","author":"Rodriguez-Barbosa","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"2021043008200710000_9.4.e002189.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2011.09.018"},{"key":"2021043008200710000_9.4.e002189.25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300894"},{"key":"2021043008200710000_9.4.e002189.26","doi-asserted-by":"publisher","DOI":"10.1038\/ni1554"},{"key":"2021043008200710000_9.4.e002189.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002840"},{"key":"2021043008200710000_9.4.e002189.28","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.1800039"},{"key":"2021043008200710000_9.4.e002189.29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trsl.2016.09.004","article-title":"Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier","volume":"181","author":"Del Rio","year":"2017","journal-title":"Transl Res"},{"key":"2021043008200710000_9.4.e002189.30","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-019-0282-2"},{"key":"2021043008200710000_9.4.e002189.31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/cei.12974","article-title":"Exosomes carrying immunoinhibitory proteins and their role in cancer","volume":"189","author":"Whiteside","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"2021043008200710000_9.4.e002189.32","unstructured":"www.cancer.ca . Stages of chronic lymphocytic leukemia (CLL) - Canadian Cancer Society [Internet]. Available: https:\/\/www.cancer.ca:443\/en\/cancer-information\/cancer-type\/leukemia-chronic-lymphocytic-cll\/staging\/?region=on [Accessed cited 2021 Feb 18]."},{"key":"2021043008200710000_9.4.e002189.33","doi-asserted-by":"publisher","DOI":"10.1038\/nature12675"},{"key":"2021043008200710000_9.4.e002189.34","doi-asserted-by":"crossref","first-page":"ji1901481","DOI":"10.4049\/jimmunol.1901481","article-title":"Galectin-9 and vista expression define terminally exhausted T cells in HIV-1 infection","volume":"204","author":"Shahbaz","year":"2020","journal-title":"J Immunol"},{"key":"2021043008200710000_9.4.e002189.35","doi-asserted-by":"crossref","first-page":"2081-2095","DOI":"10.4049\/jimmunol.1700742","article-title":"Erythroid Suppressor Cells Compromise Neonatal Immune Response against Bordetella pertussis","volume":"199","author":"Dunsmore","year":"2017","journal-title":"J Immunol"},{"key":"2021043008200710000_9.4.e002189.36","doi-asserted-by":"crossref","unstructured":"Namdar A , Dunsmore G , Shahbaz S . CD71+ erythroid cells exacerbate HIV-1 susceptibility, mediate trans-infection. and Harbor Infective Viral Particles. mBio [Internet] 2019;10.","DOI":"10.1128\/mBio.02767-19"},{"key":"2021043008200710000_9.4.e002189.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01731-2"},{"key":"2021043008200710000_9.4.e002189.38","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.21015"},{"key":"2021043008200710000_9.4.e002189.39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40364-020-00222-3","article-title":"Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia","volume":"8","author":"Yun","year":"2020","journal-title":"Biomark Res"},{"key":"2021043008200710000_9.4.e002189.40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00310"},{"key":"2021043008200710000_9.4.e002189.41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.24.8629"},{"key":"2021043008200710000_9.4.e002189.42","doi-asserted-by":"publisher","DOI":"10.1038\/nri1083"},{"key":"2021043008200710000_9.4.e002189.43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41423-019-0344-8","article-title":"Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment","volume":"17","author":"Zhao","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2021043008200710000_9.4.e002189.44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004380"},{"key":"2021043008200710000_9.4.e002189.45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4112"},{"key":"2021043008200710000_9.4.e002189.46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0022"},{"key":"2021043008200710000_9.4.e002189.47","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2422"},{"key":"2021043008200710000_9.4.e002189.48","doi-asserted-by":"publisher","DOI":"10.1038\/nri3536"},{"key":"2021043008200710000_9.4.e002189.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.09.013"},{"key":"2021043008200710000_9.4.e002189.50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-618470"},{"key":"2021043008200710000_9.4.e002189.51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59806"},{"key":"2021043008200710000_9.4.e002189.52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-342436"},{"key":"2021043008200710000_9.4.e002189.53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000947"},{"key":"2021043008200710000_9.4.e002189.54","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00262-020-02500-3","article-title":"CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancreatic cancer","volume":"69","author":"Liu","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2021043008200710000_9.4.e002189.55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00261","article-title":"Aberrant expressions of co-stimulatory and Co-inhibitory molecules in autoimmune diseases","volume":"10","author":"He","year":"2019","journal-title":"Front Immunol"},{"key":"2021043008200710000_9.4.e002189.56","doi-asserted-by":"crossref","unstructured":"Reiser J , Banerjee A . Effector, Memory, and Dysfunctional CD8+ T Cell Fates in the Antitumor Immune Response [Internet]. Journal of Immunology Research. Hindawi 2016;2016:e8941260.","DOI":"10.1155\/2016\/8941260"},{"key":"2021043008200710000_9.4.e002189.57","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3107"},{"key":"2021043008200710000_9.4.e002189.58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2337"},{"key":"2021043008200710000_9.4.e002189.59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-825265"},{"key":"2021043008200710000_9.4.e002189.60","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40364-020-0185-8","article-title":"Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML","volume":"8","author":"Tan","year":"2020","journal-title":"Biomark Res"},{"key":"2021043008200710000_9.4.e002189.61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001849"},{"key":"2021043008200710000_9.4.e002189.62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0513"},{"key":"2021043008200710000_9.4.e002189.63","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31827806e6"},{"key":"2021043008200710000_9.4.e002189.64","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.062950"},{"key":"2021043008200710000_9.4.e002189.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2007.01.091"},{"key":"2021043008200710000_9.4.e002189.66","doi-asserted-by":"crossref","unstructured":"L A , De S HP . Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than \u201cExhaustion\u201d of Human CD8 T Cells [Internet] Frontiers in immunology. Front Immunol 2013;4 https:\/\/pubmed.ncbi.nlm.nih.gov\/24391639\/","DOI":"10.3389\/fimmu.2013.00455"},{"key":"2021043008200710000_9.4.e002189.67","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-1074-3","article-title":"The role of exosomal PD-L1 in tumor progression and immunotherapy","volume":"18","author":"Xie","year":"2019","journal-title":"Mol Cancer"},{"key":"2021043008200710000_9.4.e002189.68","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/cbr.2018.2449","article-title":"The role of inflammatory cytokines in creating T cell exhaustion in cancer","volume":"33","author":"Sabzevary-Ghahfarokhi","year":"2018","journal-title":"Cancer Biother Radiopharm"},{"key":"2021043008200710000_9.4.e002189.69","first-page":"4180","article-title":"Chronic lymphocytic Leukemia\u2013Derived IL-10 suppresses antitumor immunity","volume":"200","author":"Alhakeem","year":"2018","journal-title":"J.i."},{"key":"2021043008200710000_9.4.e002189.70","doi-asserted-by":"publisher","DOI":"10.1016\/0925-5710(95)00395-9"},{"key":"2021043008200710000_9.4.e002189.71","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0876-6"},{"key":"2021043008200710000_9.4.e002189.72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060370"},{"key":"2021043008200710000_9.4.e002189.73","doi-asserted-by":"crossref","unstructured":"Baba T , Mukaida N . Role of macrophage inflammatory protein (MIP)-1\u03b1\/CCL3 in leukemogenesis. Mol Cell Oncol [Internet] 2014;1.","DOI":"10.4161\/mco.29899"},{"key":"2021043008200710000_9.4.e002189.74","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031377"},{"key":"2021043008200710000_9.4.e002189.75","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04118.x"},{"key":"2021043008200710000_9.4.e002189.76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4049\/jimmunol.202.Supp.195.9","article-title":"Il-6, IL-8 drive LAG3\/PD1 immune suppression on effector and na\u00efve, peripheral blood CD8+ T cells in cancer patients","volume":"202","author":"Somasundaram","year":"2019","journal-title":"J Immunol"},{"key":"2021043008200710000_9.4.e002189.77","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701268767"},{"key":"2021043008200710000_9.4.e002189.78","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.67.6.757"},{"key":"2021043008200710000_9.4.e002189.79","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs257"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-002189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T03:27:53Z","timestamp":1698982073000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-002189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":79,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,30]]},"published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1136\/jitc-2020-002189"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-002189","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}